Tacere Inks HCV Deal with Pfizer, Hinting Big Pharma Is Warming to Expressed RNAi

The deal, which could be worth more than $145 million to Tacere, marks the first time a big pharma has partnered on an expressed RNAi drug and helps validate Tacere’s decision not to expand into small-molecule drug development.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.